Clinical trials
Phase 3 Head and Neck Neoplasms trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Terminated | 5 |
| Active, not recruiting | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Radboud University Medical Center | 2 |
| AstraZeneca | 1 |
| Boehringer Ingelheim | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Eli Lilly and Company | 1 |
| GlaxoSmithKline | 1 |
| Hoffmann-La Roche | 1 |
| Johannes Gutenberg University Mainz | 1 |
| Merck KGaA, Darmstadt, Germany | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Head and Neck Neoplasms | 17 |
| Squamous Cell Carcinoma of Head and Neck | 8 |
| Laryngeal Diseases | 3 |
| Carcinoma, Squamous Cell | 2 |
| Neoplasms | 2 |
| Adenocarcinoma | 1 |
| Bronchial Diseases | 1 |
| Carcinoma | 1 |
| Carcinoma, Bronchogenic | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.